FAQs Sign up for updates

Want to know the latest on AUM's products?

Sign up today to get the most exclusive discounts offers
 
 
   

Why Use FANA Oligos for RNA Silencing?

FANA Oligos vs. siRNAs
The basics
Not Required Transfection Reagents Required
FANA proprietary technology allows very high specificity for the target RNA Specificity siRNA grade specificity
None RISC associated Off target effects Yes
Very easy and convenient single step process Transition from basic cell lines to primary cells to animal models Require extensive optimization and use of delivery reagents
Ease of use in different model systems
Very easy to use (No transfection reagents required). Just mix FANA oligos with the cells Basic Cell lines Need transfection reagents. transfection reagent based optimization required
Very easy to use (No transfection reagents required). Just mix FANA oligos with the cells Primary cells and difficult to transfect cells Need transfection reagents that kills the sensitive cells and sometimes alter the biology
Can easily work in fish models (especially zebrafish) Fish models Not recommended for fish models
Key Attributes
Non-toxic Toxicity Can be toxic
Resistant to degradation by serum and cellular nucleases Stability Moderate stability
Very easy optimization Resources and time saving Require additional reagents and machines. Time consuming optimization
At least - 30% more cost effective both in terms of time and money Cost saving Expensive to use

Comparison of FANA ASO and siRNA mode of action

As opposed to the RNAi pathway (involving RISC) FANA single-stranded antisense oligonucleotides use RNase H-mediated cleavage (Fig.1). This mode of mRNA knockdown is simpler than siRNA mediated knockdown and eliminates RISC-associated offtarget effects often observed with siRNA. Unlike siRNAs that are processed in the cytoplasm, FANA oligos can go into the nucleus and can be used to target RNA present within the nucleus. Most importantly FANAs can be self delivered and do not need transfection reagents or delivery agents.

Comments on FANA

Award Winning Technology

We would like to congratulate Dr. Mayumi Takahashi, Beckman Research Institute of City of Hope, California on receiving the Dr. Alan M. Gewirtz Memorial Scholarship. This award is given to outstanding scientists and recognizes their contributions in the field of oligonucleotide therapeutics. In her work, Dr. Takahashi used FANA ASOs to inhibit HIV-1 replication with a goal to develop FANA based therapeutics for HIV.

Publications on FANA

FANA sugar modifictation significantly enhances chemical stability

J.K. Watts, A.Katolik, J. Viladoms and M.J. Damha (2009), Studies on the hydrolytic stability of 2’-fluoroarabinonucleic acid (2’F-ANA), Organic & Biomolecular Chemistry, 7:1904-1910.

Click to view publication
Days of using transfection reagents are over. FANA oligos are easily taken up by the cells without transfection or delivery agents

N. Souleimanian, G.F. Deleavey, H. Soifer, S. Wang, K. Tiemann, M.J. Damha and C.A. Stein (2012), Antisense 2’-deoxy-2’-fluoroarabinonucleic acids (2’F-ANAs) antisense oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids, Molecular Therapy-Nucleic Acids, Sep 18; 1:e43; doi: 10.1038/mtna.2012.35.

Click to view publication
FANA sugar modifictation significantly enhances chemical stability

J.K. Watts, A.Katolik, J. Viladoms and M.J. Damha (2009), Studies on the hydrolytic stability of 2’-fluoroarabinonucleic acid (2’F-ANA), Organic & Biomolecular Chemistry, 7:1904-1910.

Click to view publication
Days of using transfection reagents are over. FANA oligos are easily taken up by the cells without transfection or delivery agents

N. Souleimanian, G.F. Deleavey, H. Soifer, S. Wang, K. Tiemann, M.J. Damha and C.A. Stein (2012), Antisense 2’-deoxy-2’-fluoroarabinonucleic acids (2’F-ANAs) antisense oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids, Molecular Therapy-Nucleic Acids, Sep 18; 1:e43; doi: 10.1038/mtna.2012.35.

Click to view publication
FANA sugar modifictation significantly enhances chemical stability

J.K. Watts, A.Katolik, J. Viladoms and M.J. Damha (2009), Studies on the hydrolytic stability of 2’-fluoroarabinonucleic acid (2’F-ANA), Organic & Biomolecular Chemistry, 7:1904-1910.

Click to view publication
Days of using transfection reagents are over. FANA oligos are easily taken up by the cells without transfection or delivery agents

N. Souleimanian, G.F. Deleavey, H. Soifer, S. Wang, K. Tiemann, M.J. Damha and C.A. Stein (2012), Antisense 2’-deoxy-2’-fluoroarabinonucleic acids (2’F-ANAs) antisense oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids, Molecular Therapy-Nucleic Acids, Sep 18; 1:e43; doi: 10.1038/mtna.2012.35.

Click to view publication

Protocols

Much more convenient than siRNA, shRNA or CRISPR

in vitro

No Transfection Reagents Needed (Self-Delivery Or Gymnosis)

We take pride in having the simplest protocol for RNA silencing studies. FANA oligos can work with any cell type without causing toxicity. FANA can work with easy to transfect, hard to transfect (like primary cells, b-cells, t-cells, neurons etc.) and highly sensitive patient samples.

More..

in vivo

No Delivery Vehicle, Formulations Or Conjugates Needed

It is recommended to test a few doses of FANA oligos. Recommended dose is between 3 – 30 mg/kg in mice. Administration routes: Depending upon your experimental purpose you may choose from Subcutaneous, Intrathecal, Oral or Intestinal.

More..

About us

AUM BioTech is a Philadelphia based biotechnology company with a revolutionary nucleic acids platform in the gene silencing and regulation space. AUM’s FANA RNA silencing and regulation technology can be used to very efficiently target a variety of RNA modalities like – mRNA, microRNA and long non-coding RNA. FANA technology can be used for discovery, translational and potentially for therapeutic development. Considering the versatility of our next generation RNA silencing and regulation platform AUM is now making the FANA technology available to biomedical researchers across the globe.